UPDATE: J.P. Morgan Initiates bluebird bio at Overweight on Unique & Necessary Medical Products

In a report published on Monday, J.P. Morgan analyst Cory Kasimov initiated coverage on bluebird bio BLUE with an Overweight rating and a $44 price target.

In the report, J.P. Morgan stated, "Catchy titles aside, bluebird bio is anything but “Old School.” Quite the contrary. In our view, BLUE – with its gene therapy platform – is one of the more potentially transformative and disruptive companies we've come across in some time. Importantly, however, this appears to be more than just a “big idea.” bluebird has already established promising proof-of-concept for its two lead products and is going after orphan indications with a very high unmet medical need that could bolster the ultimate probability of success."

bluebird bio closed on Friday at $30.65.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorInitiationAnalyst RatingsCory KasimovJ.P.Morgan
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!